Suppr超能文献

我们可以从父母那里学到什么来增强参与药物警戒?

What can we learn from parents about enhancing participation in pharmacovigilance?

机构信息

Institute of Psychology, Health and Society, University of Liverpool, Liverpool, UK.

出版信息

Br J Clin Pharmacol. 2013 Apr;75(4):1109-17. doi: 10.1111/j.1365-2125.2012.04441.x.

Abstract

AIMS

To investigate parents' views and experiences of direct reporting of a suspected ADR in their child.

METHODS

We audio-recorded semi-structured qualitative interviews with parents of children with suspected ADRs. Our sample included parents with (n = 17) and without (n = 27) previous experience of submitting a Yellow Card.

RESULTS

Parents in both groups described poor awareness of the Yellow Card Scheme. Parents who had participated in the Yellow Card Scheme were generally happy to report their child's ADR via the Scheme and valued the opportunity to report concerns independently of health practitioners. They expressed motivations for reporting that have not previously been described linked to the parental role, including how registering a concern about a medicine helped to resolve uncomfortable feelings about their child's ADR. Parents who had not previously submitted a Yellow Card expressed uncertainty about the legitimacy of their involvement in reporting and doubts about the value of the information that they could provide.

CONCLUSION

Promoting wider participation in pharmacovigilance schemes will depend on raising public awareness. Additionally, our findings point to the need to empower lay people to submitting reports and to reassure them about the value of their reports.

摘要

目的

调查父母对其子女疑似不良反应直接报告的看法和经验。

方法

我们对有(n=17)和无(n=27)既往提交黄卡经验的疑似不良反应儿童的父母进行了半结构化定性访谈,并对访谈进行了录音。

结果

两组父母均对黄卡计划的知晓度较差。参加过黄卡计划的父母普遍乐于通过该计划报告其子女的不良反应,并重视有机会独立于医疗保健提供者报告他们的担忧。他们表达了报告的动机,这些动机与父母的角色有关,包括记录对药物的担忧有助于消除他们对子女不良反应的不适感受。以前没有提交过黄卡的父母对自己参与报告的合法性表示不确定,对他们可以提供的信息的价值表示怀疑。

结论

促进更广泛地参与药物警戒计划将取决于提高公众意识。此外,我们的研究结果表明,有必要赋予非专业人员提交报告的权力,并让他们相信他们的报告的价值。

相似文献

1
What can we learn from parents about enhancing participation in pharmacovigilance?
Br J Clin Pharmacol. 2013 Apr;75(4):1109-17. doi: 10.1111/j.1365-2125.2012.04441.x.
6
Tokenism or true partnership: Parental involvement in a child's acute pain care.
J Clin Nurs. 2019 May;28(9-10):1491-1505. doi: 10.1111/jocn.14747. Epub 2019 Jan 11.
8
9
Parental reporting of adverse drug reactions in South Africa: An online survey.
Afr J Prim Health Care Fam Med. 2021 Sep 29;13(1):e1-e8. doi: 10.4102/phcfm.v13i1.2880.

引用本文的文献

2
Factors that influence patient and public adverse drug reaction reporting: a systematic review using the theoretical domains framework.
Int J Clin Pharm. 2023 Aug;45(4):801-813. doi: 10.1007/s11096-023-01591-z. Epub 2023 May 29.
4
Parental reporting of adverse drug reactions in South Africa: An online survey.
Afr J Prim Health Care Fam Med. 2021 Sep 29;13(1):e1-e8. doi: 10.4102/phcfm.v13i1.2880.
5
Consumer opinions on adverse events associated with medicines and vaccines.
Patient Prefer Adherence. 2018 Jul 31;12:1383-1392. doi: 10.2147/PPA.S167396. eCollection 2018.
6
Patient Reporting in the EU: Analysis of EudraVigilance Data.
Drug Saf. 2017 Jul;40(7):629-645. doi: 10.1007/s40264-017-0534-1.
7
Factors affecting patient reporting of adverse drug reactions: a systematic review.
Br J Clin Pharmacol. 2017 Apr;83(4):875-883. doi: 10.1111/bcp.13159. Epub 2016 Nov 25.
8
The value of patient reporting to the pharmacovigilance system: a systematic review.
Br J Clin Pharmacol. 2017 Feb;83(2):227-246. doi: 10.1111/bcp.13098. Epub 2016 Oct 12.
9
ADR Reporting by the General Public: Lessons Learnt from the Dutch and Swedish Systems.
Drug Saf. 2015 Apr;38(4):337-47. doi: 10.1007/s40264-015-0264-1.
10
Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance.
Springerplus. 2014 Nov 26;3:695. doi: 10.1186/2193-1801-3-695. eCollection 2014.

本文引用的文献

1
Experiences with adverse drug reaction reporting by patients: an 11-country survey.
Drug Saf. 2012 Jan 1;35(1):45-60. doi: 10.2165/11594320-000000000-00000.
2
Survey to assess public awareness of patient reporting of adverse drug reactions in Great Britain.
J Clin Pharm Ther. 2012 Apr;37(2):161-5. doi: 10.1111/j.1365-2710.2011.01273.x. Epub 2011 May 18.
3
A patient's perspective: the impact of adverse drug reactions on patients and their views on reporting.
J Clin Pharm Ther. 2012 Apr;37(2):148-52. doi: 10.1111/j.1365-2710.2011.01258.x. Epub 2011 May 18.
5
Assessing the usability of methods of public reporting of adverse drug reactions to the UK Yellow Card Scheme.
Health Expect. 2012 Dec;15(4):433-40. doi: 10.1111/j.1369-7625.2011.00686.x. Epub 2011 Apr 27.
6
The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective.
Br J Clin Pharmacol. 2011 Nov;72(5):806-22. doi: 10.1111/j.1365-2125.2011.03990.x.
8
Patient views and experiences of making adverse drug reaction reports to the Yellow Card Scheme in the UK.
Pharmacoepidemiol Drug Saf. 2011 May;20(5):523-31. doi: 10.1002/pds.2117. Epub 2011 Feb 17.
9
New rules will allow EU patients to report drug concerns directly.
BMJ. 2010 Sep 28;341:c5344. doi: 10.1136/bmj.c5344.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验